Results 111 to 120 of about 35,525 (153)

Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know? [PDF]

Tzu Chi Med J
Wu DA, Hsu BG, Lin YL.
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis. [PDF]

World J Diabetes
Chai SY, Zhang RY, Ning ZY, Zheng YM, Swapnil R, Ji LN.   +5 more
europepmc   +1 more source

The clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Khan MS, Hashmi TM, Jehangir H, Akram MF, Munawar I, Jagani SD, Maqsood M, Khalid A, Ijaz M, Saeed U, Jafar U, Ehsan M, Tuglo LS, Rehman WU, Sabouni MA, Braiteh N, Yarkoni A, Patel K.   +17 more
europepmc   +1 more source

Effects of sodium-glucose co-transporter-2 inhibitors on the risk of nephrolithiasis and urinary tract infections in Thai patients with type 2 diabetes: a hospital-based cohort study. [PDF]

Diabetol Metab Syndr
Lukkunaprasit T, Tansawet A, Siriyotha S, Looareesuwan P, Yang J, Kunakorntham P, Sirisreetreerux P, Anothaisintawee T, McKay GJ, Attia J, Thakkinstian A.   +10 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near. [PDF]

Front Pediatr
Portalatin GM, Hong-McAtee I, Burgner AM, Gould ER, Hunley TE.   +4 more
europepmc   +1 more source

Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review. [PDF]

Ann Med Surg (Lond)
Fawwad SH, Patel MS, Dziugieł S, Alfaki R, Tamoor Akhtar Shaikh M, Khanal K, Lamichhane P, Barali S.   +7 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs. [PDF]

J Vet Med Sci
Umezawa M, Fujii Y, Orito K, Yoshimoto R.   +3 more
europepmc   +1 more source

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure. [PDF]

J Cardiovasc Dev Dis
Jurin I, Ivanović Mihajlović V, Šakić Z, Pavlov M, Šipić T, Vitlov P, Falak H, Grizelj D, Manola Š, Udovičić M.   +9 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus.

Indian J Pharmacol
Bellapu D, Darwin R.
europepmc   +1 more source

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

openaire   +1 more source